Literature DB >> 22949379

A multifactorial likelihood model for MMR gene variant classification incorporating probabilities based on sequence bioinformatics and tumor characteristics: a report from the Colon Cancer Family Registry.

Bryony A Thompson1, David E Goldgar, Carol Paterson, Mark Clendenning, Rhiannon Walters, Sven Arnold, Michael T Parsons, Walsh Michael D, Steven Gallinger, Robert W Haile, John L Hopper, Mark A Jenkins, Loic Lemarchand, Noralane M Lindor, Polly A Newcomb, Stephen N Thibodeau, Joanne P Young, Daniel D Buchanan, Sean V Tavtigian, Amanda B Spurdle.   

Abstract

Mismatch repair (MMR) gene sequence variants of uncertain clinical significance are often identified in suspected Lynch syndrome families, and this constitutes a challenge for both researchers and clinicians. Multifactorial likelihood model approaches provide a quantitative measure of MMR variant pathogenicity, but first require input of likelihood ratios (LRs) for different MMR variation-associated characteristics from appropriate, well-characterized reference datasets. Microsatellite instability (MSI) and somatic BRAF tumor data for unselected colorectal cancer probands of known pathogenic variant status were used to derive LRs for tumor characteristics using the Colon Cancer Family Registry (CFR) resource. These tumor LRs were combined with variant segregation within families, and estimates of prior probability of pathogenicity based on sequence conservation and position, to analyze 44 unclassified variants identified initially in Australasian Colon CFR families. In addition, in vitro splicing analyses were conducted on the subset of variants based on bioinformatic splicing predictions. The LR in favor of pathogenicity was estimated to be ~12-fold for a colorectal tumor with a BRAF mutation-negative MSI-H phenotype. For 31 of the 44 variants, the posterior probabilities of pathogenicity were such that altered clinical management would be indicated. Our findings provide a working multifactorial likelihood model for classification that carefully considers mode of ascertainment for gene testing.
© 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22949379      PMCID: PMC3538359          DOI: 10.1002/humu.22213

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  76 in total

1.  The germline MLH1 K618A variant and susceptibility to Lynch syndrome-associated tumors.

Authors:  Fabiola Medeiros; Noralane M Lindor; Fergus J Couch; W Edward Highsmith
Journal:  J Mol Diagn       Date:  2012-03-13       Impact factor: 5.568

2.  Prevalence of germline mutations of MLH1 and MSH2 in hereditary nonpolyposis colorectal cancer families from Spain.

Authors:  Trinidad Caldes; Javier Godino; Miguel de la Hoya; Iciar Garcia Carbonero; Pedro Perez Segura; Charis Eng; Manuel Benito; Eduardo Diaz-Rubio
Journal:  Int J Cancer       Date:  2002-04-10       Impact factor: 7.396

3.  CpG island methylator phenotype in colorectal cancer.

Authors:  M Toyota; N Ahuja; M Ohe-Toyota; J G Herman; S B Baylin; J P Issa
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-20       Impact factor: 11.205

4.  Prediction and assessment of splicing alterations: implications for clinical testing.

Authors:  Amanda B Spurdle; Fergus J Couch; Frans B L Hogervorst; Paolo Radice; Olga M Sinilnikova
Journal:  Hum Mutat       Date:  2008-11       Impact factor: 4.878

5.  Colon Cancer Family Registry: an international resource for studies of the genetic epidemiology of colon cancer.

Authors:  Polly A Newcomb; John Baron; Michelle Cotterchio; Steve Gallinger; John Grove; Robert Haile; David Hall; John L Hopper; Jeremy Jass; Loïc Le Marchand; Paul Limburg; Noralane Lindor; John D Potter; Allyson S Templeton; Steve Thibodeau; Daniela Seminara
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-11-02       Impact factor: 4.254

6.  BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer.

Authors:  Guoren Deng; Ian Bell; Suzanne Crawley; James Gum; Jonathan P Terdiman; Brian A Allen; Brindusa Truta; Marvin H Sleisenger; Young S Kim
Journal:  Clin Cancer Res       Date:  2004-01-01       Impact factor: 12.531

7.  BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair.

Authors:  Liang Wang; Julie M Cunningham; Jennifer L Winters; Jennifer C Guenther; Amy J French; Lisa A Boardman; Lawrence J Burgart; Shannon K McDonnell; Daniel J Schaid; Stephen N Thibodeau
Journal:  Cancer Res       Date:  2003-09-01       Impact factor: 12.701

8.  Gastrointestinal cancers and neurofibromatosis type 1 features in children with a germline homozygous MLH1 mutation.

Authors:  Steven Gallinger; Melyssa Aronson; Katayoon Shayan; Elyanne M Ratcliffe; Justin T Gerstle; Patricia C Parkin; Heidi Rothenmund; Marina Croitoru; Ewa Baumann; Peter R Durie; Rosanna Weksberg; Aaron Pollett; Robert H Riddell; Bo Y Ngan; Ernest Cutz; Alain E Lagarde; Helen S L Chan
Journal:  Gastroenterology       Date:  2004-02       Impact factor: 22.682

9.  Maximum entropy modeling of short sequence motifs with applications to RNA splicing signals.

Authors:  Gene Yeo; Christopher B Burge
Journal:  J Comput Biol       Date:  2004       Impact factor: 1.479

10.  A yeast two-hybrid assay provides a simple way to evaluate the vast majority of hMLH1 germ-line mutations.

Authors:  Emiko Kondo; Hideyuki Suzuki; Akira Horii; Shinichi Fukushige
Journal:  Cancer Res       Date:  2003-06-15       Impact factor: 12.701

View more
  35 in total

1.  RNA analysis of cancer predisposing genes in formalin-fixed paraffin-embedded tissue determines aberrant splicing.

Authors:  Anne Ml Jansen; Heleen M van der Klift; Marieke Ae Roos; Jaap Dh van Eendenburg; Carli Mj Tops; Juul T Wijnen; Frederik J Hes; Hans Morreau; Tom van Wezel
Journal:  Eur J Hum Genet       Date:  2018-04-30       Impact factor: 4.246

2.  Using Somatic Mutations from Tumors to Classify Variants in Mismatch Repair Genes.

Authors:  Brian H Shirts; Eric Q Konnick; Sarah Upham; Tom Walsh; John Michael O Ranola; Angela L Jacobson; Mary-Claire King; Rachel Pearlman; Heather Hampel; Colin C Pritchard
Journal:  Am J Hum Genet       Date:  2018-06-07       Impact factor: 11.025

3.  Classifying MMR variants: time for revised nomenclature in Lynch syndrome.

Authors:  Y Nancy You; Eduardo Vilar
Journal:  Clin Cancer Res       Date:  2013-03-26       Impact factor: 12.531

4.  Gene variants of unknown clinical significance in Lynch syndrome. An introduction for clinicians.

Authors:  Rolf H Sijmons; Marc S Greenblatt; Maurizio Genuardi
Journal:  Fam Cancer       Date:  2013-06       Impact factor: 2.375

5.  MicroRNA target for MACC1 and CYR61 to inhibit tumor growth in mice with colorectal cancer.

Authors:  Guiqi Wang; Jingfeng Gu; Yingchao Gao
Journal:  Tumour Biol       Date:  2016-08-04

6.  Lynch syndrome with exclusive skin involvement: time to consider a molecular definition?

Authors:  Alessandro Vaisfeld; Martina Calicchia; Maria Grazia Pomponi; Emanuela Lucci-Cordisco; Luca Reggiani-Bonetti; Maurizio Genuardi
Journal:  Fam Cancer       Date:  2019-10       Impact factor: 2.375

Review 7.  Genetic predisposition to colorectal cancer: syndromes, genes, classification of genetic variants and implications for precision medicine.

Authors:  Laura Valle; Eduardo Vilar; Sean V Tavtigian; Elena M Stoffel
Journal:  J Pathol       Date:  2019-02-20       Impact factor: 7.996

8.  Role of tumour molecular and pathology features to estimate colorectal cancer risk for first-degree relatives.

Authors:  Aung Ko Win; Daniel D Buchanan; Christophe Rosty; Robert J MacInnis; James G Dowty; Gillian S Dite; Graham G Giles; Melissa C Southey; Joanne P Young; Mark Clendenning; Michael D Walsh; Rhiannon J Walters; Alex Boussioutas; Thomas C Smyrk; Stephen N Thibodeau; John A Baron; John D Potter; Polly A Newcomb; Loïc Le Marchand; Robert W Haile; Steven Gallinger; Noralane M Lindor; John L Hopper; Dennis J Ahnen; Mark A Jenkins
Journal:  Gut       Date:  2014-03-10       Impact factor: 23.059

9.  Cohort Profile: The Colon Cancer Family Registry Cohort (CCFRC).

Authors:  Mark A Jenkins; Aung Ko Win; Allyson S Templeton; Maggie S Angelakos; Daniel D Buchanan; Michelle Cotterchio; Jane C Figueiredo; Stephen N Thibodeau; John A Baron; John D Potter; John L Hopper; Graham Casey; Steven Gallinger; Loic Le Marchand; Noralane M Lindor; Polly A Newcomb; Robert W Haile
Journal:  Int J Epidemiol       Date:  2018-04-01       Impact factor: 7.196

10.  A comparison of cosegregation analysis methods for the clinical setting.

Authors:  John Michael O Rañola; Quanhui Liu; Elisabeth A Rosenthal; Brian H Shirts
Journal:  Fam Cancer       Date:  2018-04       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.